Carbohydrate-dependent B cell activation by fucose-binding bacterial lectins by Wilhelm, I. et al.
Wilhelm et al., Sci. Signal. 12, eaao7194 (2019)     5 March 2019
S C I E N C E  S I G N A L I N G  |  R E S E A R C H  A R T I C L E
1 of 17
H O S T - P A T H O G E N  I N T E R A C T I O N S
Carbohydrate-dependent B cell activation by  
fucose-binding bacterial lectins
Isabel Wilhelm1,2,3*, Ella Levit-Zerdoun4,5,6*, Johanna Jakob7, Sarah Villringer1,3,  
Marco Frensch1,3,5, Rudolf Übelhart7, Alessia Landi1,3, Peter Müller1,3, Anne Imberty8, 
Roland Thuenauer1,3, Julie Claudinon1,3, Hassan Jumaa7, Michael Reth1,3,4,  
Hermann Eibel9,10, Elias Hobeika7†‡, Winfried Römer1,2,3†‡
Bacterial lectins are typically multivalent and bind noncovalently to specific carbohydrates on host tissues to fa-
cilitate bacterial adhesion. Here, we analyzed the effects of two fucose-binding lectins, BambL from Burkholderia 
ambifaria and LecB from Pseudomonas aeruginosa, on specific signaling pathways in B cells. We found that these 
bacterial lectins induced B cell activation, which, in vitro, was dependent on the cell surface expression of the 
B cell antigen receptor (BCR) and its co-receptor CD19, as well as on spleen tyrosine kinase (Syk) activity. The 
resulting release of intracellular Ca2+ was followed by an increase in the cell surface abundance of the activation 
marker CD86, augmented cytokine secretion, and subsequent cell death, replicating all of the events that are 
observed in vitro upon canonical and antigen-mediated B cell activation. Moreover, injection of BambL in mice 
resulted in a substantial, BCR-independent loss of B cells in the bone marrow with simultaneous, transient en-
largement of the spleen (splenomegaly), as well as an increase in the numbers of splenic B cells and myeloid cells. 
Together, these data suggest that bacterial lectins can initiate polyclonal activation of B cells through their sole 
capacity to bind to fucose.
INTRODUCTION
Pseudomonas and Burkholderia species are proteobacteria, which 
release various lectins and form biofilms (1, 2). These bacteria cause 
opportunistic infections and exhibit multidrug antibiotic resistance 
(2–4). Burkholderia ambifaria belongs to the Burkholderia cepacia 
complex, a group of closely related bacterial strains, which cause 
so-called cepacia syndrome (4). The fatal combination of necrotizing 
pneumonia, respiratory failure, and bacteremia has been observed 
in the lung infections of patients suffering from cystic fibrosis (CF), 
as well as in nosocomial infections of other immunocompromised 
hosts (5–7). Furthermore, B. ambifaria species were identified in a 
polyclonal bacteremia outbreak caused by contaminated ultrasound 
gel in Brazil in 2015, but the epidemiology of B. ambifaria remains 
poorly characterized to date (7).
In addition to many other virulence factors, these bacteria produce 
soluble carbohydrate-binding proteins, so-called lectins. Pseudomonas 
aeruginosa expresses two tetravalent lectins, LecA and LecB (also called 
PA-IL and PA-IIL), with carbohydrate-binding specificities for ga-
lactose and fucose, respectively (8). The B. ambifaria lectin BambL 
(gene annotation across databases: bamb_5415; UniProt-ID: Q0B4G1_
BURCM; NCBI-ProteinID: ABI90962; KEGG-ID: bam:Bamb_5415) 
contains six carbohydrate-binding sites (9). Both LecB and BambL 
display exceptionally high affinities for fucose, with the respective 
Kd (dissociation constant) values in the micromolar range, which is 
rather unusual for a lectin-monosaccharide interaction (9). Several 
studies point to an underestimated, highly complex role of bacterial 
lectins in affecting host cellular processes, going far beyond an ad-
hesive function (10–14). In particular, there is very limited knowl-
edge about the influence of soluble bacterial lectins on cells of the 
immune system (15, 16).
However, many receptors of immune cells, including the B cell 
antigen receptor (BCR), are highly glycosylated and thus present 
potential targets for lectins (17–19). The BCR, which is expressed by 
B lymphocytes, plays a pivotal role in the humoral immune response. 
In mammals, B lymphocyte development follows a strict, multistep 
maturation program starting in the bone marrow from hematopoietic 
stem cells through progenitor (pro-) to precursor (pre-) cell stages. 
The pre–B cells are defined by their expression of the pre-BCR and 
further develop into immature B cells, which mainly express a BCR of 
the immunoglobulin M (IgM) isotype (20, 21). Subsequently, these 
immature B cells migrate to the periphery and secondary lymphoid 
organs such as the spleen and the lymph nodes, where they undergo 
further differentiation, eventually coexpressing IgM- and IgD-BCR 
isotypes of the same antigen specificity. IgD expression increases with 
progressing differentiation with mature B cells expressing more IgD 
than IgM (20, 22).
The BCR comprises two heavy chains (HCs), two light chains (LCs), 
and the Ig/Ig (CD79a/CD79b) heterodimer, which functions as the 
signaling component of the BCR complex (23–25). Mature B cells also 
carry a co-receptor complex comprising the molecules CD19, CD81, 
and CD21 (26). After B cell activation, CD19 is found in close proxim-
ity to the IgM-BCR and signals through the phosphoinositide 3-kinase 
(PI3K) pathway (27). B cell survival and differentiation are also 
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promoted by the B cell–activating factor of the tumor necrosis factor 
(TNF) family (BAFF), which is also known as B-Lys (28, 29). The BCR 
can be activated by monovalent and polyvalent antigens (30, 31). IgD- 
BCRs are specialized in the binding of multivalent antigens, whereas 
IgM-BCRs can bind to both types of antigen (30, 32, 33).
The constant region of both IgM- and IgD-BCRs is N-glycosylated 
with glycans of the complex type, whereas the pre-BCR is highly 
mannosylated (18). Fucosylated epitopes can be part of N-linked or 
O-linked sugar chains. However, because of the challenges in resolv-
ing the glycosylation patterns of the BCR with spectrometric tech-
niques, the exact amounts and sites, particularly of O-linked glycans, 
have not been elucidated to date (34–36). Furthermore, the number 
and position of N-linked glycosylation sites may vary between mu-
rine and human BCRs (34, 36). However, there are indications that 
glycosylation events can affect B cell development in mice, wherein a 
specific glycosylation site (Asn46, N46) on IgM is required for efficient 
pre-BCR function and further B cell maturation (17). Furthermore, 
the glycosylation pattern of the BCR changes during carcinogenesis: 
Follicular lymphoma cells acquire carbohydrates of the high man-
nose type in the variable domain of the BCR, generating binding sites 
for mannose-binding lectins (19, 37). Moreover, the Ig and whole 
BCR molecules carry altered glycans in chronic lymphocytic leuke-
mia, influencing BCR signaling (38).
In this study, we found that the fucose-specific bacterial lectins 
BambL and LecB bound to murine B cells and induced an intracel-
lular signaling cascade that changed the flux of Ca2+. In vitro, acti-
vation of this cascade by BambL required expression of the BCR, as 
well as of its co-receptor CD19. Stimulation by BambL induced ca-
nonical BCR-mediated signaling events that resulted in a polyclonal 
B cell death, which was partially reversed by BAFF-induced signaling. 
In vivo, intraperitoneal injection of BambL resulted in lymphopenia in 
the bone marrow combined with a transient splenomegaly, as well as 
accumulation of B cells and myeloid cells in the spleen. These events 
were independent of BCR signaling because they were recapitulated in 
BCR-deficient mice. We propose that these bacterial lectins act as 
superstimulatory antigens, activating B cells in a BCR- dependent 
manner in vitro by binding to fucosylated epitopes and eliciting a 
strong, but transient, BCR-independent immune response in vivo.
RESULTS
BambL induces Ca2+ release that is dependent on BCR 
expression and Syk activity
Upon antigen binding, the immunoreceptor tyrosine-based activa-
tion motifs of the Ig/ subunits are phosphorylated, activating an 
intracellular signaling cascade (23, 39). As a part of the second mes-
senger cascade, the intracellular Ca2+ concentration changes by store- 
operated calcium entry through the Ca2+ release–activated Ca2+ 
channels (40, 41). To assess whether the two fucose-binding lectins, 
LecB and BambL, activated primary murine B cells, we performed in-
tracellular Ca2+ flux measurements in vitro (Fig. 1). The hexavalent 
BambL (10 g/ml) induced a Ca2+ release similar to that induced by BCR 
stimulation with anti-κ (hereafter anti-kappa) antibodies (10 g/ml) 
in mature follicular (MFo) B cells (Fig. 1A). Saturating the BambL 
carbohydrate binding sites with soluble l-fucose (25 mg/ml) prevented 
BambL binding to B cells (fig. S1A) and Ca2+ flux (Fig. 1A), indicating 
that this activation process was fucose specific. The mitogenic poten-
tial of LecB on murine splenocytes was described previously (15). 
Here, we demonstrated that binding of the tetravalent LecB (10 g/ml) 
to B cells also induced a Ca2+ signal but to a somewhat lesser 
extent than that induced by the hexavalent BambL (Fig. 1A).
To assess whether the strength of lectin binding correlated with 
the extent of Ca2+ flux, we analyzed the binding of both lectins by 
flow cytometry and found that both lectins bound to B cells. LecB is 
tetravalent with a molecular mass of 46.924 kDa, whereas BambL is 
hexavalent with a molecular mass of 28.143 kDa. Because of its hexa-
valency, the avidity of BambL is increased, which resulted in higher 
binding capacity at similar concentrations in comparison to LecB 
(fig. S1A). The binding capacity may be further influenced by the 
differences in BambL lectin structure in comparison to LecB, as well 
as the affinity of BambL for different host cell receptors. Furthermore, 
the lower MW of BambL supposedly leads to the binding of more 
molecules per cell (fig. S1A). With BambL and LecB showing simi-
lar effects on B cells, we focused on the characterization of BambL 
binding. Additional binding assays demonstrated that BambL bound 
to all CD19-positive splenic B cells, as well as T cells (fig. S1B). An-
alyzing Ca2+ mobilization in response to BambL binding in terms of 
dose dependency, we found a clear correlation in the range between 
0.1 and 10 g/ml of the lectin (Fig. 1B). To dissect the role of indi-
vidual components of the BCR-associated signaling cascade in the 
response to BambL, we analyzed Ca2+ mobilization using B cells from 
mice lacking spleen tyrosine kinase (Syk), the Src-family kinase Lyn, 
or the BCR HC. Syk and Lyn are the most proximal kinases to the 
BCR and are involved in canonical B cell activation (25, 42). Similar 
to the Ca2+ release upon BCR stimulation by anti-IgM F(ab′)2, the 
BambL-mediated Ca2+ release was independent of Lyn but required 
the presence of the kinase Syk (Fig. 1C). Note that BambL efficiently 
bound to Syk-deficient B cells (fig. S1C). Stimulation with anti-IgM 
served as a control for Ca2+ release in these experiments; however, 
because of normalization of the y axis to the BambL-mediated Ca2+ 
release experiments, we cannot directly compare our data to those 
from previous studies (42, 43).
In a similar approach, we monitored Ca2+ release in B cells lack-
ing surface BCR expression using mice carrying a B1-8 HC allele 
flanked by loxP sites (B1-8fl) on an inducible mb1-CreERTT2 “deleter” 
background (44, 45). These mice express a B cell–specific Cre recom-
binase from the Ig-encoding mb-1 locus, which, upon tamoxifen 
treatment, induces the deletion of the B1-8fl allele, resulting in the 
generation of HC-deficient B cells. The HC-deficient B cells were ob-
tained at day 7 after tamoxifen treatment when an abundant number 
of these cells were still present in mb1-CreERT2; B1-8fl mice before 
they were lost at later time points (44–46). These cells (denoted as 
HC−/− cells), identified by gating on IgM- and IgD-negative popula-
tions (fig. S1D), displayed no detectable Ca2+ flux when stimulated 
with BambL despite effectively binding BambL (Fig. 1D and fig. S1E). 
The efficiency of tamoxifen-induced Cre-mediated recombination 
is not 100% in the mb1-CreERT2; B1-8fl mice. Only about 15 to 20% 
of B cells lost HC 7 days after tamoxifen treatment. Therefore, IgM- 
and IgD-positive B cells were still detected in these animals and served 
as an internal HC-sufficient control (HC+/+ cells; Fig. 1D and fig. S1C). 
These data indicate that BambL-dependent activation of B cells re-
quires the presence of the BCR and Syk to mobilize intracellular Ca2+ 
and is abrogated in the presence of l-fucose.
BambL-induced B cell activation is restricted to  
IgD-expressing B cells
We next examined whether activation of B cells by BambL dif-
fered between pre– and mature B cells. To this end, we compared 
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Fig. 1. BCR and Syk are essential for 
BambL-induced Ca2+ release in pri-
mary B cells. (A) Flow cytometric 
analysis of Ca2+ release in splenic (SP) 
CD93− MFo B cells from wild-type (WT) 
mice upon stimulation with BambL 
(10 g/ml), LecB (10 g/ml), or anti- 
kappa F(ab′)2 [10 g/ml; hereafter, 
a-kappa F(ab′)2] antibody (Ab) as a 
control. BambL preincubated with 
l-fucose served as a control for BambL 
fucose-binding specificity. Data are 
representative of four independent 
experiments. (B) Dose-dependent 
stimulation of MFo B cells with BambL 
was monitored by flow cytometric 
analysis of Ca2+ release (left) and bind-
ing of BambL (right) to these cells. For 
the binding analysis, the relative flu-
orescence of BambL-Cy5 over time is 
shown. Data are representative of three 
independent experiments. (C) Flow 
cytometric analysis of Ca2+ release in 
WT (black) and Syk−/− (red, top) or 
Lyn−/− (red, bottom) MFo B cells, stim-
ulated with BambL (10 g/ml; left) or 
anti-IgM F(ab′)2 [10 g/ml; hereafter, 
a-IgM F(ab′)2] Ab (right). Data are rep-
resentative of three independent 
experiments. (D) Flow cytometric anal-
ysis of Ca2+ release in BCR-negative 
B cells (HC−/−, red) as well as in BCR- 
sufficient B cells from the same mouse 
(HC+/+, black). Cells were stimulated 
with BambL (10 g/ml; left) or anti- 
IgM F(ab′)2 (10 g/ml; right). Data are 
representative of four independent 
experiments. The gating strategy for 
HC−/− cells and the HC+/+ control is 
depicted in fig. S1C.
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BambL-triggered Ca2+ release in bone marrow–derived and splenic 
B cells. We stained bone marrow–derived and splenic B cells with 
antibodies to detect the expression of typical cell surface markers to 
distinguish among the different B cell maturation stages (fig. S2). In 
contrast to incubation of the cells with anti-IgM F(ab′)2, incubation 
with BambL did not result in Ca2+ flux in pre–B cells or immature 
B cells (Fig. 2A), although BambL bound to both subsets of cells 
(fig. S2B). Similarly, transitional 1 (T1) B cells from the spleen did not 
release Ca2+, whereas splenic T2/T3, marginal zone (MZ), and MFo 
B cells displayed changes in intracellular Ca2+ concentrations upon 
treatment with BambL (Fig. 2A). Immature and T1 B cells express 
little to no IgD (fig. S2D) (22); therefore, we suspected that the acti-
vation of mature B cells by BambL was IgD dependent. To test this 
hypothesis, we analyzed BambL-induced Ca2+ flux using bone 
marrow–derived B cells from IgM−/− mice (47). In these mice, the 
DNA sequences encoding the constant region of the HC have been 
removed, enforcing the expression of IgD starting from early matu-
ration stages. We observed that BambL increased intracellular Ca2+ 
concentrations in these B cells (Fig. 2B). These data demonstrate that 
the IgM-BCR was not required for BambL-induced Ca2+ release and 
suggest that the IgD, but not the IgM, isotype of the BCR is required 
for BambL-induced Ca2 + release in mature B cells.
B cell blasts treated with the Toll-like receptor 4 (TLR4) agonist 
lipopolysaccharide (LPS) down-regulate cell surface IgD and differ-
entiate into IgMhigh plasmablasts (48). We therefore compared Ca2+ 
release in LPS-treated B cells isolated from WT and IgM−/− mice, 
which had been crossed with Blimp-1GFP mice. In the latter, a green 
fluorescent protein (GFP) reporter is expressed from the Prdm1 gene 
locus, which encodes the transcription factor Blimp-1, a master reg-
ulator of plasma cell development expressed at early stages of plasma 
cell differentiation (49, 50). Plasmablasts were identified on the basis of 
the expression of GFP and the plasma cell marker Syndecan-1 (CD138). 
WT plasmablasts displayed only a moderate Ca2+ release upon ex-
posure to BambL, whereas IgM−/− plasmablasts, which expressed only 
IgD, exhibited a greater intracellular Ca2+ response (Fig. 2C). These 
results further support our hypothesis that only IgD-bearing B cells 
are activated by BambL.
BambL-induced murine B cell activation also requires CD19
To corroborate our findings that BambL mobilized Ca2+ only in 
IgD+ B cells, we compared changes in Ca2+ concentration in IgM- and 
in IgD-deficient B cells after incubation with different concentrations 
of BambL. As expected, we observed that the IgD−/− B cells expressing 
only IgM (fig. S3) were able to bind to BambL but failed to mobilize 
Ca2+, which was in contrast to the responses of WT B cells and B cells 
expressing IgD alone (Fig. 3, A and B). Because the IgD-BCRs of 
resting mature B lymphocytes are reportedly organized in “protein 
islands” with the co-receptor CD19 in close proximity (51, 52), we 
assumed that the IgD-dependent activation of B cells by BambL 
might also involve CD19. Although CD19-deficient B cells bound to 
BambL to a similar extent as did WT B cells, they released much less 
Ca2+ than did WT B cells upon exposure to BambL (Fig. 3, C and D). 
B cells from mice lacking both IgD and CD19 but expressing IgM 
(identified by CD19 and IgD staining; fig. S3) were still able to bind 
to BambL but did not mobilize the intracellular Ca2+ flux even at a 
very high BambL concentration (10 g/ml) (Fig. 3, C and D). To-
gether, these data suggest that the surface expression of both IgD 
and CD19 is indispensable for the BambL-induced activation of pri-
mary mature B cells.
CD19, IgM, and IgD are internalized upon BambL binding
Upon binding to the BCR of a cognate antigen, the receptor com-
plex becomes internalized by endocytosis (53). Because CD19 and 
IgD were essential for BambL-mediated B cell activation, we tested 
whether BambL induced the endocytosis of these surface molecules. 
As another control, we also monitored the cell surface expression of 
IgM. After 16 hours of incubation with BambL, murine B cells ex-
pressed substantially reduced amounts of CD19, IgD, and, unexpect-
edly, also of IgM on the surface compared to those of unstimulated 
cells or B cells stimulated with anti-IgM (Fig. 4, A and B). Moreover, 
the effects were inhibited in the presence of l-fucose (Fig. 4, A and B). 
We assumed that binding to and subsequent internalization of CD19, 
IgD, and IgM were specific, because other heavily glycosylated mol-
ecules, such as B220 (CD45R), showed no decrease in cell surface 
abundance after 16 hours of incubation with BambL (fig. S4). To-
gether, these observations demonstrate that BambL leads to the in-
ternalization of CD19, IgD, and, to a lesser degree, IgM.
BambL induces an increase in CD86 abundance and  
TNF- secretion
To further elucidate the physiological effects of BambL-mediated 
activation, we sought to determine whether early B cell activation 
markers, such as CD86 (B7.2), were increased in response to BambL 
(54). CD86 is a highly glycosylated molecule and was internalized 
upon BambL incubation (fig. S5A). Thus, we established a “BambL 
wash-out” protocol in which B cells were first incubated with BambL 
at 37°C for 15 min, then washed to remove unbound lectin, and left 
overnight to recover. We found that the increase in CD86 abundance in 
response to BambL was similar to that induced after activation with the 
TLR ligands cytosine-phosphate-guanine (CpG) oligonucleotides and 
LPS, although not to the same extent as that in response to anti-IgM 
F(ab′)2 (Fig. 5, A and B). The addition of l-fucose resulted in BambL 
inducing only a moderate increase in CD86 cell surface expression.
To confirm that the observed effect was dependent on the presence 
of the BCR rather than on an artifact caused by pattern recognition 
receptor stimulation, we assessed the response of BCR-deficient B cells 
to BambL. We did not observe an increase in CD86 abundance in these 
cells after BambL stimulation (Fig. 5C). Initial signaling events, such 
as Ca2+ flux, induce the differentiation of lymphocytes into effector 
cells. For B lymphocytes, the spectrum of effector cell function includes 
the secretion of cytokines (55). Analyzing the supernatants of BambL- 
treated B cells, we detected a marked increase in TNF- production 
(fig. S5B) and secretion (Fig. 5D). TNF- secretion by B cells is re-
ported to be an outcome of canonical nuclear factor B (NF-B) sig-
naling (56), which suggests that BambL activates the NF-B pathway. 
In summary, treatment of B cells with BambL results in a sustained 
increase in CD86 abundance.
BambL leads to B cell death, which is partially reversible  
by BAFF
Strong intracellular signaling can drive B cells into activation-induced 
cell death (57–59). Because BambL binding to B cells resulted in the 
IgD- and CD19-dependent activation of intracellular signaling cas-
cades, we tested the survival of splenic B cells after stimulation. After 
24 hours of incubation with BambL, B cell viability decreased in a 
concentration-dependent manner (Fig. 6A). To characterize the type 
of BambL-induced cell death, we performed further viability assays 
using various inhibitors, which targeted pathways related to apop-
tosis, pyroptosis, and necroptosis. Pyroptosis can be induced by 
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infection with Gram-negative bacteria (in-
cluding Burkholderia) but has rarely been 
observed in B cells (60–62). The initia-
tion of pyroptosis is thought to depend 
on caspase-1 activity (63); however, treat-
ment of primary B cells with the caspase-1 
inhibitor did not alter BambL-mediated 
cytotoxicity (fig. S6A). In contrast, the sur-
vival of BambL-treated B cells increased 
upon their treatment with the apoptosis 
inhibitor QVD, and treatment with the 
necroptosis inhibitor Nec-1 resulted in 
detectable rescue effects (fig. S6A). Thus, 
B cells exposed to BambL most likely suc-
cumb to a combination of apoptosis and 
necroptosis.
Binding of BAFF to its receptor BAFF-R 
activates essential survival functions in 
transitional and mature B cells (29). We, 
therefore, tested whether BAFF could re-
verse or prevent BambL-induced cell death. 
However, coincubation with BAFF over-
night only restored the viability of BambL- 
treated B cells by about 20% (Fig. 6B). In a 
4-day time course experiment with a sub-
lethal concentration of BambL, we observed 
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Fig. 2. IgD-expressing B cell subsets release Ca2+ 
upon treatment with BambL. (A) Flow cytomet-
ric analysis of Ca2+ release in WT B cells at different 
developmental stages: bone marrow (BM)–derived 
pre–B cells (gray), immature B cells (red), and mature 
B cells (black). Cells were stimulated with BambL 
(5 g/ml; left) or anti-IgM F(ab′)2 (10 g/ml; right). 
The BM gating strategy is shown in fig. S2A. The 
splenic (SP) subsets are displayed in the middle 
and bottom panels. Middle: CD93+; transitional 1 
(T1, red) and T2/3 (black). Bottom, CD93−; MFo 
(red) B cells and MZ (black) B cells. The SP gating 
strategy is depicted in fig. S2C. The relative cell sur-
face IgD expression of the respective B cell sub-
types is shown in fig. S2D. Data are representative 
of five independent experiments. (B) Flow cytomet-
ric analysis of Ca2+ release in IgM−/− BM-derived 
B cells at different developmental stages. Cells were 
stimulated with BambL (5 g/ml; left) or anti-kappa 
F(ab′)2 (10 g/ml; right). BM subsets are displayed 
as pre–B cells (gray), immature B cells (red), and 
mature B cells (black). Data are representative of three 
independent experiments. (C) Flow cytometric anal-
ysis of Ca2+ release in WT (black) and IgM−/− (red) 
plasmablasts after 4 days of incubation with LPS. Top: 
Representative analysis of the cell surface expres-
sion of CD19, IgD, and IgM. Cells were selected on 
the basis of Blimp-GFP and Syndecan-1 (CD138) 
expression. The cells were stimulated with BambL 
(5 g/ml; bottom left) or anti-kappa F(ab′)2 (10 g/ml; 
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an increase in the viability of BambL-treated 
B cells in the presence of BAFF (fig. S6B). 
This increased survival was not due to BAFF- 
dependent changes in BambL binding (Fig. 6C). 
Together, these results suggest that BambL 
induces B cell death, which can be partially 
rescued by BAFF.
In vivo administration of BambL leads 
to splenomegaly and the loss of  
B cells from the bone marrow
To address the in vivo relevance of our in vitro 
findings, we injected BambL (15 mg/kg) in-
traperitoneally into WT mice and assessed the 
effects of BambL at days 3 and 7. We decided to 
use this concentration based on our observa-
tion that BambL is bound by soluble Igs: Coin-
cubation with Igs neutralized BambL, reducing 
its binding to B cells and subsequently dimin-
ishing the intracellular Ca2+ release (fig. S7).
The mice were healthy before and after in-
jection; the application of BambL did not lead 
to weight loss or any other macroscopically 
detectable side effects. At day 3 after BambL 
application, the mice exhibited splenomegaly 
with the spleens being on average 2.7-fold 
heavier compared to those of phosphate- 
buffered saline (PBS)–injected control mice 
(Fig. 7, A and B). On day 7, the spleen weights 
were statistically significantly reduced com-
pared to those on day 3 but were still about 
twofold heavier than the spleens from the con-
trol mice (Fig. 7, A and B).
The total B cell numbers in the spleens 
of BambL-treated mice were markedly in-
creased, mainly due to the changes in the 
numbers of MFo, T1, and T2/3 populations 
(Fig. 7, C and D; for gating strategy, see fig. 
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Fig. 3. IgD and CD19 play a major role in BambL- 
induced signaling. (A) Flow cytometric analysis of Ca2+ 
release in SP-derived MFo B cells (SP CD93−) from WT 
(black) and IgM−/− (red; top, n = 3) and IgD−/− (red; bot-
tom, n = 4) mice. Cells were stimulated with BambL 
(250 ng/ml; left), anti-IgD F(ab′)2 (10 g/ml; top right), 
or anti-IgM F(ab′)2 (10 g/ml; bottom right). (B) Flow 
cytometric analysis of BambL-Cy5 binding to the cor-
responding B cells: WT (left), IgM−/− (middle), and IgD−/− 
(right). Data are representative of at least three inde-
pendent experiments. (C) Flow cytometric analysis of 
Ca2+ release in WT (black), CD19−/− (red; top, n = 3), 
and CD19−/−IgD−/− (red; bottom, n = 3) B cells. Cells 
were stimulated with BambL (5 or 10 g/ml; left) or 
anti-IgM F(ab′)2 (10 g/ml; right). (D) Flow cytometric 
analysis of BambL-Cy5 binding to the corresponding 
B cells: WT (left), CD19−/− (middle), and CD19−/−IgD−/− 
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affected (fig. S8B). The absolute cell counts of these populations had 
declined by day 7 (Fig. 7, C and D; for gating strategy, see fig. S8A). 
MZ B cell numbers were not affected in BambL-treated mice 
(Fig. 7D; for gating strategy, see fig. S8A). Because of the successful 
inhibition of cell death by QVD in vitro (fig. S6A) and its reported 
applicability in vivo (64, 65), we decided to coinject QVD with 
BambL into WT mice to investigate the influence of caspases on 

































































































Fig. 4. Binding of BambL leads to the internalization of CD19, IgD, and IgM and can be blocked by soluble l-fucose. (A) Purified splenic MFo B cells from WT mice 
were stimulated ex vivo in the presence of BambL (2.5 g/ml), BambL (2.5 g/ml) blocked with l-fucose (25 mg/ml), or anti-IgM F(ab′)2 and analyzed by flow cytometry 
after 16 hours of incubation for the cell surface expression of CD19, IgD, and IgM. Unstimulated cells served as a negative control for receptor expression. The combination 
of BambL and l-fucose served as a control for the specificity of BambL. Anti-IgM F(ab′)2 served as a positive control for BCR activation. Viable cells were selected using a 
fixable viability dye. Data are representative of six independent experiments. (B) Statistical analysis of data shown in (A). Mean values of one representative analysis with 
at least three technical replicates ± SD are shown. For statistical analysis, a Student’s t test was performed. **P < 0.01; ***P < 0.001. MFI, mean fluorescence intensity.
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the para-caspase mucosa-associated lymphoid tissue lymphoma 
translocation protein 1 (MALT-1) have been described to play essen-
tial roles in B cell differentiation, death, and survival (59, 66, 67). 
We analyzed the BambL- and QVD- treated animals at day 3 after 
injection, when the full potential of the inhibitor could still be 
assumed. However, co-application of QVD in vivo did not statisti-
cally significantly affect either the size of the spleens or the B cell 
numbers in the spleen (Fig. 7, A to D).
In the bone marrow, lymphopenia was detected on day 3 after in-
jection of BambL, which was marked by the loss of total B cells among 
which the pre–, immature, and recirculation B cell subpopulations 
were statistically significantly reduced (Fig. 7, E and F; for gating 
strategy, see fig. S8C), whereas the total numbers of bone marrow–
derived cells were not changed (fig. S8D). Similar to its effects in the 
spleen, QVD did not rescue the BambL-induced reduction in B cell 
numbers in the bone marrow (Fig. 7, E and F). The numbers of mature 
recirculating B cells were statistically significantly increased by day 7 
compared to day 3 after injection with BambL alone or with QVD 
(Fig. 7E), suggesting that the B cell numbers were likely restored 
over time. Together, these data suggest that BambL induced a transient 
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Fig. 5. BambL mediates an increase in CD86 ex-
pression and TNF- secretion. (A) Purified splenic 
MFo B cells from WT mice were stimulated ex vivo in 
the presence of the indicated stimuli (see Materials 
and Methods for concentrations used). CD86 served 
as an activation marker, and its cell surface expres-
sion was assessed 16 hours after stimulation. BambL 
(5 g/ml) was washed out after 15 min of stimula-
tion at 37°C. Unstimulated cells served as a nega-
tive control for CD86 expression. The combination 
of BambL and l-fucose served as a control for the 
specificity of BambL. Anti-IgM F(ab′)2, LPS, and CpG 
served as positive controls for BCR and TLR activa-
tion. Viable cells were selected using a fixable via-
bility dye. Data are from one experiment and are 
representative of three independent experiments. 
(B) Fold changes in the MFI of CD86 from three in-
dependent biological replicate experiments. Cells 
treated with BambL were compared to the untreated 
control cells. (C) BCR-negative, Ig−/− B cells were 
treated as described in (A) and examined by flow cytometry to determine the cell surface expression of CD86. The cells were obtained 10 days after tamoxifen treatment. Data 
are representative of at least three experiments. (D) B cells were stimulated for 16 hours with BambL (2.5 g/ml), LPS (10 g/ml), or BambL (2.5 g/ml) + l-fucose (25 mg/ml). 
The cell culture media were collected and analyzed by enzyme-linked immunosorbent assay (ELISA) to determine the amount of TNF- released. Data are means ± SD of 
three independent experiments and were analyzed by Student’s t test to assess the statistical significance of observed differences. ***P < 0.001; ns, not significant.
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splenomegaly and expansion of B cells in the spleen with simultaneous 
loss of B cells from the bone marrow.
BambL administration induces the accumulation of myeloid 
cells in the spleen
During the analysis of BambL-injected mice, we observed an accumu-
lation of large and granulated cells by flow cytometric analysis (fig. 
S8E). To determine the exact lineage of this population, we stained the 
splenocytes and bone marrow–derived cells for myeloid surface mark-
ers and calculated the absolute cell counts of myeloid populations based 
on a previously described gating strategy (68, 69). On day 3 after 
BambL injection, we found that the amount of total CD11b+ cells was 
statistically significantly increased in the spleen, specifically neutrophils, 
eosinophils, macrophages, and dendritic cells (DCs) (Fig. 8, A and B; 
for gating strategy, see fig. S9A). The cell numbers of these populations, 
with the exception of eosinophils, were reduced by day 7 (Fig. 8, 
A and B). We further distinguished inflammatory and circulating 
monocyte populations, which were still increased in number on day 7 
(Fig. 8C). The addition of QVD did not substantially affect the num-
bers of total CD11b+ cells in BambL-treated mice. The inflammatory 
monocytes were statistically significantly increased in number after 
coinjection with QVD compared to those from mice treated only with 
BambL. In the bone marrow, the numbers of myeloid cells were not 
statistically significantly changed upon injection with BambL alone 
or together with QVD (Fig. 8, D to F; gating strategy, fig. S9B).
We stained the splenic and bone marrow–derived cells with the 
Red Flica active polycaspases kit and Sytox viability dye to assess 
caspase activity. On the basis of a similar gating strategy as one de-
scribed earlier (fig. S8, A and B), we identified the individual B cell 
compartments as well as the total non–B cell population. We sub-
sequently analyzed these populations by plotting Red Flica versus 
Sytox, which enabled us to assess the caspase activity (Red Flica+), 
to detect later stages of apoptosis (Red Flica+Sytox+), and to exclude 
necrotic cells (Sytox+). We found statistically significantly increased 
caspase activity (Red Flica+) in splenic non–B cell populations, which 
was reduced after QVD application (fig. S10, A and B, left). In the bone 
marrow, only the pro–B cells exhibited caspase activity, wherein the 
Red Flica+Sytox+ population (late apoptotic cells) was statistically 
significantly increased (fig. S10, C to F).
In vivo expansion of splenic B cells is independent of BCR 
signaling and of B cell development in the bone marrow
To assess whether the observed in vivo phenotype after BambL in-
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Fig. 6. BAFF partially reverses B cell death induced by BambL. (A) Purified 
splenic MFo B cells from WT mice were stimulated with the indicated concentra-
tions of BambL. Cell viability was assessed after 24 hours in parallel with that of an 
unstimulated control by flow cytometric analysis using the viability dye. Data are 
means ± SD from three independent experiments and were analyzed by Student’s 
t test to assess statistical significance. ***P < 0.001; ****P < 0.0001. (B) Purified 
splenic MFo B cells from WT mice were stimulated ex vivo in the presence of BambL 
(2.5 g/ml) with or without BAFF costimulation. The cells were analyzed 24 hours later 
by flow cytometry to generate forward scatter (FSC) and side scatter (SSC) plots and 
viability dye histograms. Cells negative for the viability dye were considered to be 
alive, whereas those cells positive for the dye were considered to be dead. Data are 
representative of four independent experiments. (C) Flow cytometric analysis of 
the binding of BambL- Cy5 to MFo B cells in the presence and absence of soluble 
BAFF (100 ng/ml). Data are representative of three independent experiments.
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wherein we inactivated BCR expression by conditionally deleting 
Ig. We used the IgTMF mouse model (70), which we crossed with 
the mb1-CreERT2 mice. At day 10 after tamoxifen application, these 
mice had inactivated Ig expression and subsequently lost BCR sur-
face expression. We chose this mouse line for the in vivo experiments 
because the deletion of the Ig-encoding locus in these mice was more 
efficient (about 70 to 90% BCR-negative B cells) compared to the in-
activation of the HC in the mb1-CreERT2; B1-8fl mice (about 15 to 
20% BCR-negative B cells), which we had used in our earlier in vitro 
experiments. Analogously to WT mice, the mb1-CreERT2; IgTMF 
mice (referred to as IgTMF mice for simplicity) were injected with 
BambL (15 mg/kg). On day 3 after injection, these mice exhibited 
splenomegaly with splenic weights increased twofold in BambL-treated 
versus PBS-treated animals (fig. S11, A and B). By staining the B cells 
from the IgTMF mice with anti-IgM and anti-IgD antibodies, we 
confirmed that about 70 to 90% of all B cells were BCR negative (fig. 
S11C). We further observed an increase in the number of total B cells 
in the spleen, most likely due to an increased number of MFo B cells, 
because the transitional and MZ compartments were not substan-
tially affected (fig. S11, D and E). Similar to WT mice, the T cell num-
bers were not changed (fig. S8B). In the bone marrow, the total cell 
numbers were not markedly altered, whereas the absolute B cell counts 
were reduced; here, specifically pro–, pre–, and immature B cell com-








































































































































































P = 0.0150 
WT + PBS
WT + BambL day 3
WT + BambL + QVD day 3
WT + BambL day 7
WT + PBS
WT + BambL day 3
WT + BambL + QVD day 3
WT + BambL day 7
WT + PBS
WT + BambL day 3
WT + BambL + QVD day 3
WT + BambL day 7
0.0082P =
0.031P =
Fig. 7. Intraperitoneal injection of mice with BambL leads to splenomegaly and accumulation of B cells in the spleen with simultaneous lymphopenia in the 
bone marrow. (A) Images of spleens for the indicated times and treatment conditions after mice were injected with BambL. The sizes of the spleens were directly com-
pared after extraction. Scale bar is given in centimeters. (B) Statistical analysis of spleen weights from the indicated groups of treated mice. (C and D) Statistical analysis 
of the numbers of the indicated B cell populations in the indicated groups of treated mice. (E and F) Absolute counts of the indicated B cell populations in the bone 
marrow of the indicated groups of treated mice. In (B) to (F), each dot indicates an individual mouse: PBS, n = 10; BambL d3, n = 7; BambL + QVD d3, n = 4; BambL d7, n = 4. 
The data represent a compilation of values from four to seven independent experiments. All P values were obtained using a two-tailed Student’s t test.
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splenic and bone marrow cells, see fig. S11, H and I, respectively). 
In addition, myeloid cells in the spleen (fig. S11, J to L), as well as 
myeloid compartments in the bone marrow were not substantially 
changed (fig. S11, M to O).
To investigate the origin of the B cell expansion in the spleen, we 
blocked interleukin-7 receptor (IL-7R) signaling by injecting the 
mice with anti–IL-7R antibodies 7 days before we administered 
BambL, thereby arresting B cell development in the bone marrow. 
On day 3 after BambL injection (thus, day 10 after anti–IL-7R appli-
cation), we observed splenomegaly (fig. S12, A and B) and increased 
numbers of total B cells, most likely due to an expansion of the MFo 
B cell compartment (fig. S12C). Whereas T1 B cell numbers in the 
spleen were statistically significantly increased in anti–IL-7R– and 
BambL- treated mice (fig. S12, D and E), their average numbers 
were 20-fold lower compared to those of BambL-treated WT mice, 
which had not received anti–IL-7R antibodies (Fig. 7D). Consistent 
with this finding, the T2/T3 population was also reduced in num-
bers; however, it was not further affected by BambL treatment (fig. 
S12, D and E).
In the bone marrow of anti–IL-7R–treated mice, the total B cell 
numbers were about 4.5-fold less than those of untreated WT mice 
(Fig. 7E and fig. S12F). Furthermore, lymphopenia was observed 
after BambL administration, wherein the total B cell counts and the 
numbers of mature recirculating B cells in the bone marrow were re-
duced (fig. S12, F to H). The numbers of pro–, pre–, and immature 
B cells were markedly reduced because of anti–IL-7R treatment but 
were not further changed by BambL application (fig. S12, G and H). 
Last, we detected an increase in the number of neutrophils in the 
spleens and bone marrow of anti–IL-7R– and BambL-treated mice, 
whereas other myeloid lineage cells were not substantially affected 
(fig. S12, I to N). These results suggest that the BambL-induced ac-
cumulation of B cells in the spleen was most likely due to an increase 
in the number of MFo cells rather than a shift in lymphopoiesis from 
the bone marrow to the spleen. Furthermore, the lack of the mature 
recirculating population in the bone marrow demonstrates that ma-
ture B cells did not circulate but remained in the spleen.
BambL is localized in the cytosol of B. ambifaria
The cellular localization of BambL in B. ambifaria has not yet been 
investigated. We therefore assessed the subcellular localization of 
BambL in B. ambifaria biofilms on agar plates and found that the lec-
tin was not released but was exclusively retained in the cytosol of the 
bacteria (fig. S13).
DISCUSSION
Pathogens express adhesins and toxins to aid in infection and the 
colonization of host tissues. Glycan-binding factors, such as the in-
fluenza A hemagglutinin, were identified by their ability to aggregate 
red blood cells (71, 72), whereas toxins, such as Shiga toxin, were shown 
to use glycolipids on epithelial cells as docking sites for entry (11, 73). 
Here, we provide insights into the interaction between fucose-binding 
bacterial lectins and B cells and demonstrate that the lectins LecB and 
BambL trigger BCR-dependent activation in vitro, ultimately result-
ing in activation-induced death of B cells. This signaling cascade de-
pended mainly on CD19 and IgD because CD19- and IgD-deficient 
B cells failed to mobilize intracellular Ca2+ upon exposure to BambL. 
To a lesser extent, BambL also bound to IgM, as seen in the experi-
ments using high-lectin concentrations, wherein preference for IgD 
was lost. Note that studies on monovalent versus multivalent BCR 
antigens suggest that a strong burst of Ca2+ release only takes place 
after stimulation with soluble multivalent antigens (30, 74, 75). In-
teresting in this context is the finding that the hinge region of IgD is 
more flexible compared to the more rigid IgM-BCR, rendering the 
IgD molecule better suited to bind to multivalent antigens (30, 33). 















































































































WT + BambL day 3
WT + BambL + QVD day 3
WT + BambL day 7
WT + PBS
WT + BambL day 3
WT + BambL + QVD day 3
WT + BambL day 7
Fig. 8. Myeloid cell counts are increased in mice after injection with BambL. (A to C) Absolute counts of the indicated myeloid cell populations in the spleens of 
mice from the indicated treatment groups. (D to F) Absolute counts of the indicated myeloid cell populations in the bone marrow of mice from the indicated treatment 
groups. In (A) to (F), each dot indicates an individual mouse: PBS, n = 10; BambL d3, n = 7; BambL + QVD d3, n = 4; BambL d7, n = 4. The data represent a compilation of 
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signaling upon multivalent antigen triggering relies, to a large extent, 
on the function of IgD and CD19 and less on IgM (33). Whereas 
antigen binding involves the complementarity determining region 
(CDR) loops of the variable domains of the HC and LC, BambL most 
likely binds to glycan residues at the constant and hinge regions of 
the BCR, indicating a difference in mechanism, despite similarities in 
target receptor affinities. In addition, the signaling of the chemokine 
receptor CXCR4 engages BCR cross-talk by activating the actin cyto-
skeleton and also depends on IgD and CD19 expression (76). Both 
IgM and IgD possess five N-glycosylation sites at each constant re-
gion, which differ in their positions. The influence of carbohydrates 
on the regulation and activation of the BCR is not well understood at 
present. However, a study by Chen et al. demonstrated that the glyco-
proteins that surround IgD- and IgM-BCRs strongly differ and that 
this might explain their divergent signaling behaviors (77). BambL- 
induced activation resembles that induced by B cell superantigens, such 
as the microbial toxins Staphylococcus protein A or Peptostreptococcus 
protein L, which bind to conserved regions of the BCR by protein- 
protein interactions (78, 79) but are glycosylation independent.
In addition to Ca2+ release, short-term stimulation of B cells with 
BambL initiated increased cell surface CD86 expression and the ac-
tivation of effector functions, such as the secretion of TNF-. In 
canonical B cell activation, the surface expression of CD86 is increased 
to enable T cell costimulation by CD28. We found that long-term 
stimulation with BambL overnight again decreased CD86 cell surface 
expression and caused cell death. The loss of surface CD86 might be 
explained by a direct interaction with BambL: If CD86 is fucosylated, 
it will likely bind to BambL after prolonged exposure with the lectin, 
which could lead to its internalization.
After initial B cell activation, BambL induced B cell death, whereas 
cotreatment with soluble BAFF, which activates pro-survival signals 
of the noncanonical NF-B and PI3K pathways, partially protected 
the lectin-treated cells (28, 80, 81). In addition, the polycaspase in-
hibitor QVD, which blocks caspases-1, -3, -8, -9, and -12, the major 
players during apoptosis (82), and the necroptosis inhibitor Nec-1 
rescued B cells from BambL-induced cell death in vitro.
To address the role of BambL in vivo, we injected BambL intra-
peritoneally into WT and IgTMF mice. We observed a transient in-
crease in B cell numbers in the spleen, as well as splenomegaly in WT 
and IgTMF mice, which lack the surface BCR, suggesting that the 
effect of BambL on B cells in vivo was independent of BCR signaling 
but might result from stimulation of other B cell surface receptors 
(Fig. 7 and fig. S11). This phenotype is reminiscent of reports as-
cribing splenomegaly to various infections, injections with BCR- 
targeting antibodies, and the application of excess BAFF (83–85). 
The increase in splenic B cell numbers was accompanied by a loss of 
B cells in the bone marrow (Fig. 7). To reconcile the lymphopenia in 
the bone marrow with the simultaneous accumulation of B cells in 
the spleen 3 days after BambL application, we first assumed that 
BambL triggered an activation-induced migration of B cells from the 
bone marrow to the spleen. However, blocking B lymphopoiesis in 
the bone marrow with anti–IL-7R antibodies revealed that the accu-
mulation of mature B cells most likely occurred directly in the spleen 
due to the hyperproliferation of MFo cells (fig. S12). The loss of 
B cells in the bone marrow was likely due to BambL-induced en-
hanced apoptosis at the pro–B cell stage (fig. S10). Note that the B cell 
populations in the bone marrow were in the process of recovering, 
and the spleen sizes and weights, as well as splenic B cell numbers, 
decreased to almost normal levels by day 7 (Fig. 7). This is, to some 
extent, consistent with our in vitro observation that BambL triggered 
the activation-induced death of B cells (Fig. 6). However, although we 
did not detect enhanced apoptosis of splenic B cells in vivo, we cannot 
exclude the possibility that BambL induced other cell death mecha-
nisms. A study identified a previously uncharacterized proliferation- 
limiting mechanism: a DNA damage response–induced cell cycle 
arrest upon the initial hyperproliferation of Epstein-Barr virus– or 
CpG-stimulated B cells. This cell cycle arrest mechanism inhibits 
proliferation without inducing apoptosis (86). Another study dem-
onstrated that B cells transiently activated with antigen return to 
a quiescent state in the absence of T cell help (87). It is feasible that 
similar mechanisms control the initial hyperproliferation and sub-
sequent proliferation arrest upon treatment with BambL, particu-
larly because we did not observe any changes in the numbers of T cell 
populations after BambL injection, indicating a lack of enhanced T cell 
activity (fig. S8B).
We also observed a transient accumulation of myeloid lineage 
cells in the spleens of BambL-treated WT mice, including neutrophils, 
eosinophils, macrophages, and DCs (Fig. 8). This indicates that 
BambL targets not only B cells in vivo but also other cell types carry-
ing fucose-bearing receptors. It is likely that the temporary increase 
in the numbers of these cells further contributes to splenomegaly. 
In addition, myeloid lineage cells produce B cell stimulatory factors, 
including BAFF (28, 88). Because BAFF dampened BambL-induced 
B cell death in vitro (Fig. 6), increased amounts of BAFF, secreted 
by activated myeloid cells, might account for the BambL-mediated 
proliferation of B cells and protection from BambL-induced B cell 
death in vivo. Note that because caspase activity was enhanced in 
splenic non–B cell populations, we assume that BambL induced a 
temporary increase in the number of myeloid cells with subsequent 
apoptosis, thereby reducing their numbers until day 7 (Fig. S10). 
Because we partially reversed BambL-induced B cell death with the 
polycaspase inhibitor QVD in vitro, we coinjected this inhibitor into 
the BambL-treated mice but observed no substantial effect. The ac-
tivity of caspases has been described to play a role not only in the 
induction of cell death but also during the differentiation of immune 
cells (82). In our experimental setup, we only detected caspase ac-
tivity in non–B cells and pro–B cells.
B. ambifaria is a member of the B. cepacia complex (Bcc). 
Burkholderia species comprising the Bcc are often found in patients 
with CF, and they release multiple lectins, which have not been inves-
tigated to date (4, 89). It is likely that these bacteria share common 
features. For example, BambL from B. ambifaria shares a high pro-
tein sequence similarity with other lectins from B. cepacia (99%), 
Burkholderia pyroccinia (95%), and Burkholderia contaminans (94%) 
[according to a UniProt-based Basic Local Alignment Search Tool 
(BLAST) analysis]. The expression dynamics and cellular localiza-
tion of BambL in B. ambifaria are poorly studied to date. Previous 
studies reported that LecB from the B. ambifaria–related bacterium 
P. aeruginosa was located in the outer surface of the bacterial cell wall 
(10, 90). We found BambL exclusively in the cytosol of B. ambifaria 
extracts. This finding is expected because other pathogenic bacteria 
withhold their soluble lectins; for example, the lectin Shiga toxin 
B subunit is limited to the cytoplasm and periplasm (91) and is re-
leased by a triggered, phage- mediated bacterial lysis (11, 92, 93). 
Similarly, B. ambifaria may release BambL in response to specific 
environmental changes that are yet to be discovered.
Another study has correlated the expression of LecA and LecB from 
P. aeruginosa with its pathogenicity, wherein bacterial cytotoxicity 
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and adhesion were reduced in mutant LecA and LecB strains in vitro 
and the bacterial burden and dissemination of the mutant strains 
were decreased in vivo (94). Moreover, our group previously re-
ported that the invasiveness of P. aeruginosa depended directly on 
the expression of LecA (12). The role of BambL in infection in gen-
eral and in CF in particular remains elusive, and the site of B cell 
encounter with BambL in vivo is not known to date. The lymph 
nodes may not be the only sites where B cells encounter their anti-
gens. Direct interaction of B cells with bacterial proteins in the periph-
ery has been previously described (95, 96). For example, Chen et al. 
demonstrated the existence of B cells bearing IgD alone in the mu-
cosa of the upper respiratory tract that become class-switched from 
IgM in a noncanonical manner of B cell maturation (97). It is possi-
ble that the binding of BambL to soluble fucosylated proteins, such 
as antibodies, may dampen its effectiveness in vivo. However, a 
study demonstrated that circulating IgG molecules do not inhibit 
the function of Staphylococcus aureus superantigen SpA in vivo but 
rather potentiate its effects (98). We are aware that SpA binding to 
B cells is glycosylation independent; therefore, we cannot directly 
compare it to the binding of BambL to fucosylated epitopes. How-
ever, we cannot exclude the possibility that similar mechanisms 
occur during an infection with B. ambifaria or after injection with 
purified BambL.
It is important to emphasize that all of the observed changes in 
cellular physiology are likely due to the ability of the lectin to bind to 
fucosylated host cell receptors. Although BambL may bind to various 
targets in vivo, our observations suggest that the effect on mature 
BCR signaling through its glycosylated structures is underestimated. 
For the murine pre-BCR, core fucosylation has been reported to be 
indispensable for functional HC expression (99). The increase in fuco-
sylation of surface receptors on epithelial cells protects against many 
intestinal bacterial infections (100) but increases the susceptibility to 
other (for example, viral) pathogens (101). However, a direct link be-
tween fucosylation and host-pathogen signaling has been difficult to 
prove, partly due to the strong polymorphism of fucosyltransferases 
(102). Fucosylated epitopes have been identified as functional recep-
tors for the B subunit of cholera toxin, which binds specifically to GM1 
and is often used as a lipid raft marker (13). Furthermore, a viral lectin, 
the hemagglutinin of influenza A virus, has been classified as a pan–B 
cell activator through its binding to the sialic acid residues of a recon-
stituted BCR (103), resulting in the hypothesis that this carbohydrate- 
dependent and superantigen-like B cell activation mechanism might 
be evolutionarily conserved; however, bacterial lectins have not been 
included in the list of typical danger- or pathogen-associated molec-
ular patterns so far.
We propose a mechanism of B cell activation by bacteria. In vitro, 
BambL specifically binds to the fucose residues of BCRs. This inter-
action initiates diverse, crucial B cell signaling processes, which 
depend on the presence of the surface receptors IgD and CD19, and 
eventually cause B cell death. In vivo, BambL application caused a 
rapid cellular immune response, which involved not only B cells, but 
also innate immune cells, and subsided within a week. This might 
pose a risk to immunocompromised patients unable to mount an 
effective response to pathogenic particles. Whether our finding can 
be translated to a natural infection remains to be elucidated. How-
ever, this study opens up the possibility for further in-depth research 
of host-pathogen interactions and reveals that highly regulated 
mechanisms of B cell signaling and complex BCR expression pro-
grams can be hijacked by glycan-targeting bacterial lectins.
MATERIALS AND METHODS
Production of recombinant bacterial lectins
BambL (UniProt-ID: Q0B4G1_BURCM) and LecB (UniProt-ID: 
Q9HYN5_PSEAE) were expressed in Escherichia coli and purified by 
affinity chromatography, as previously described (8, 9). The freeze- 
dried powder was dissolved in PBS without Ca2+ or Mg2+ at 1 mg/ml. 
To avoid contamination by LPS, the lectins were further purified on 
endotoxin removal traps (hyglos), sterile-handled, and regularly 
checked for LPS contamination with the Pierce Limulus Amebocyte 
Lysate (LAL) chromogenic assay (Thermo Scientific). Activation ex-
periments (measurement of Ca2+ release and increased CD86 ex-
pression) included additional controls with boiled BambL (15 min at 
95°C) to exclude possible effects of heat-stable LPS contaminants origi-
nating from the recombinant protein production. For fluorescent label-
ing, the purified lectins were covalently tagged with the Alexa Fluor 488 
(Thermo Scientific), Cy-3, or Cy-5 (GE Healthcare) labeling kits accord-
ing to the manufacturers’ instructions and repurified on a Pierce ZebaSpin 
D-Salt polyacrylamide desalting column (Thermo Scientific).
Mice
All animal experiments were conducted with mice aged 8 to 12 weeks, 
were performed in accordance with the German Animal Welfare Act, 
and were reviewed by the regional council and approved under license 
number G-09/103. Mice were bred in the animal facility of the 
Max Planck Institute of Immunology and Epigenetics (Freiburg, 
Germany) and the University of Ulm (Ulm, Germany). For inducible, 
B cell–specific deletion, mice were orally administered tamoxifen 
citrate (Ratiopharm) dissolved in 20% ClinOleic (Baxter) as previously 
described (80). The course of tamoxifen treatments and the interval 
between doses were pre-optimized for maximal recovery of the mod-
ified cells and are outlined below (81). In this study, the following mice 
strains were used: C57BL/6 WT or heterozygous mEGFP/mb1inv 
(104) (GFP+ B cells); B cells from IgM−/− (47) and IgD−/− mice were 
also used (105). CD19−/− B cells were obtained from homozygous 
CD19-CreERT2 mice (provided by M. Schmidt-Supprian; Technical 
University Munich, Germany) (81, 106). To generate CD19/IgD 
double-deficient B cells, homozygous CD19-CreERT2 mice were 
crossed with homozygous IgD−/− mice and then intercrossed. HC−/− 
B cells were generated by crossing HCB1-8fl/JhT mice (44) with mb1-
CreERT2 mice and were analyzed 7 days after tamoxifen application. For 
the BambL injection experiments, IgTMF mice (70) were crossed with 
mb1-CreERT2 mice; their offspring are termed IgTMF mice in this man-
uscript for simplicity. The mice were injected with BambL at day 7 after 
tamoxifen treatment, and cells were extracted and analyzed 3 days later. 
Ig−/− B cells were generated by crossing mb1/mEGFPinv (104) mice 
with mb1-CreERT2 mice (45, 81) and were obtained on day 10 after 
tamoxifen treatment. Furthermore, we used Lyn−/− mice (107), mice 
with B cell–specific conditional Syk deletion (Syk−/−) (81), and BlimpGFP 
mice (49). The animals were euthanized using CO2, and the spleens and 
bone marrow were extracted under nonsterile conditions. B cells were 
then purified by magnetic or flow cytometry–based separation.
Isolation of murine B cells by magnetic-activated cell sorting 
depletion and flow cytometry–based sorting
Cell separation was performed by magnetic-activated cell sorting 
(MACS) depletion or flow cytometry–based sorting; spleen-derived 
B cells were obtained by MACS-based negative selection using the 
B cell isolation kit (Miltenyi Biotec) according to the manufacturer’s 
instructions. The cells were then separated using an AutoMACS 
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(Miltenyi Biotec). Spleen-derived B cells from heterozygous mEGFP/
mb1inv mice as well as GFP+ B cells from Ig−/− mice were separated 
by fluorescence-activated cell sorting (FACS) based on their abun-
dance of GFP with a FACSAria (BD) cell sorter. HC-deficient B cells 
were sorted based on the lack of IgM and IgD expression, as de-
scribed elsewhere (45). After separation, B cells were analyzed for 
purity and viability with an anti-CD19 antibody (6D5, BioLegend) 
and 7-AAD (BioLegend) or a fixable viability dye (eBioscience).
Flow cytometric analysis
Extracellular staining for flow cytometric (FACS) analysis was per-
formed with 0.5 × 106 to 1 × 106 cells/ml in FACS buffer [PBS; 3% fetal 
calf serum (FCS) and 0.05% NaN3] on ice for 20 min. Before staining, 
the cells were incubated with the anti-Fc receptor-blocking antibody 
(CD16/32, Clone 2.4G2; own production) on ice for at least 5 min. 
For the extracellular staining of B cells, the following antibodies were 
used: anti-CD19 Alexa Fluor 647 or phycoerythrin (PE) (eBio1D3; 
eBioscience and 6D5; BioLegend), anti-IgD fluorescein isothiocyanate 
(FITC) or PE (11-26c.2a; BioLegend), anti-CD23 Alexa Fluor 647 or 
PE-Cy7 (B3B4; BioLegend or 2G8; Southern Biotech), anti-CD24 
(M1/69; BioLegend), anti-CD25 (PC61.5, eBioscience), anti–BAFF-R 
biotin (polyclonal; R&D Systems), anti-IgM eFluor 450 (eB121-15F9), 
anti-CD93 PE or allophycocyanin (APC) (AA4.1), and anti-CD86 
PE (GL1) (all eBioscience). For the myeloid stainings, we used anti- 
CD11c (N418, BioLegend), anti-F4/80 (BM8, eBioscience), anti- CD11b 
(M1/70; eBioscience), anti- Ly6C (HK1.4; eBioscience), and anti-CD3 
(145-2C11, eBioscience). The cells were washed with 700 l of FACS 
buffer to remove the residual antibodies and centrifuged at 300g at 
4°C for 5 min. All antibodies used in this study were tested for lectin 
cross- reactivity before staining. CyAn Advanced Digital Processing 
(ADP) (Beckman Coulter), LSRII, and LSRFortessa (both from Becton 
Dickinson) cell analyzers were used for data acquisition. For intra-
cellular staining, cells were fixed and permeabilized using the Fix & 
Perm Kit (ADG Bio Research) and stained with anti–TNF- antibody 
(clone: MP6-XT22; eBioscience) dissolved in saponin-based buffer. 
Cytometry data were analyzed with Flow Jo software (TreeStar).
Caspase-activity assay
Cells were stained with the SR-FLICA Caspase Assay Kit (Immuno-
Chemistry Technologies) according to the manufacturer’s instruc-
tions. Briefly, the cells were isolated, stained with detection reagent 
for 1 hour at room temperature, and washed with the specific apop-
tosis buffer containing PBS, which was provided with the kit.
Ca2+ analysis and binding assays
Ca2+ flux in purified mature B cells was measured by flow cytometry 
using the cell-permeable fluorescent dye Indo-1 (Life Technologies) 
cells loaded as described previously (45). The following stimuli were 
used: anti-IgM F(ab′)2 (goat polyclonal; Jackson ImmunoResearch), 
anti-kappa F(ab′)2, and anti-IgD F(ab′)2 (both polyclonal; Southern 
Biotech). The cells were maintained in culture medium containing 
1% FCS and were treated with lectins at different concentrations, 
ranging from 250 ng/ml to 10 g/ml. Intracellular Ca2+ flux and 
extracellular binding of BambL-Cy5 were measured simultaneously 
on an LSRII flow cytometer (Becton Dickinson).
Lectin-dependent increase in CD86 cell surface abundance
B cells were seeded at 1 × 106 cells/ml in complete medium and 
stimulated in a 96-well U-bottom plate with the lectin dissolved in 
complete medium. For the binding assays, B cells were stimulated 
on ice for 15 min and then analyzed for lectin binding by flow cy-
tometry. For the “wash out” procedure, cells were stimulated with 
BambL at 37°C for 15 min, which was followed by two washing steps 
with 2 ml of PBS. As a positive control, we used polyclonal anti-IgM 
F(ab′)2 (goat polyclonal; Jackson ImmunoResearch, 10 g/ml), un-
methylated CpG oligonucleotides (Invivogen; ODN 1826, 2.5 M), 
and LPS (Sigma; 10 g/ml). The cells were harvested 16 hours after 
stimulation, and the cell surface abundance of the activation marker 
CD86 was analyzed by flow cytometry using anti-CD86 (clone, GL1; 
eBioscience).
Measurement of TNF- by ELISA
The concentration of secreted TNF- was measured by ELISA. The 
extracted splenic B cells were treated with BambL overnight, and the 
cell culture medium was collected by centrifugation and subsequent 
filtration. The amount of TNF- released was determined using the 
anti-mouse TNF- Ready-Set-Go ELISA Kit (eBioscience) accord-
ing to the manufacturer’s instructions.
Survival assays
Primary, spleen-derived murine B cells were purified and cultured 
at 37°C and 7.5% CO2 in complete medium, Iscove’s modified 
Dulbecco’s medium (IMDM) (Biochrom, Merck) supplemented with 
10% heat- inactivated FCS, 1% Gibco Penicillin-Streptomycin [peni-
cillin (100 U/ml)–streptomycin (100 g/ml)], and 2 mM Gibco l- 
glutamine (all from Thermo Scientific). The cells were incubated either 
in medium alone or in the presence of human recombinant BAFF 
(100 ng/ml) (hrBAFF, ImmunoTools) over a period of 4 days. The 
medium was exchanged every second day and supplemented with 
fresh hrBAFF. Cell viability was assessed with a fixable viability dye 
(eBioscience). Annexin V and propidium iodide staining was not appli-
cable for the survival assays because of reported false positivity by cat-
fish egg lectin (108). For the viability analysis, the percentages were 
obtained from the ungated, viability dye–negative (healthy) cells. The 
following inhibitors were first titrated on B cells and then used in this 
study: necrostatin (Nec-1), polycaspase inhibitor QVD (Q-VD-PH), 
and caspase-1 inhibitor Z-WEHD-FMK (all from R&D Biosystems).
Intraperitoneal injection of BambL
Expecting that a major fraction of BambL would be intercepted by 
soluble Igs and carbohydrates expressed on erythrocytes, we decided 
to inject BambL in PBS (without adjuvants) intraperitoneally instead 
of intravenously. In a dose-dependency study, we determined the con-
centration of 15 mg/kg to be comparable to the doses of BCR-targeting 
antibodies that had been used previously (84). Control mice received 
the same volume of PBS intraperitoneally. Seven days after injection, 
we extracted the spleens and bone marrow to further analyze the cells 
by flow cytometry. Experimental mice did not suffer at any point of 
the intraperitoneal treatment experiments and did not lose any body 
weight during the study. QVD was coapplied at 20 mg/kg, as sug-
gested by the manufacturer (R&D Biosystems).
BambL localization in B. ambifaria
Bacteria were fractionated on the basis of the LecB localization pro-
tocol for P. aeruginosa published by Tielker et al. (10). B. ambifaria 
strain HSJ1 was grown as a biofilm on agar plates [tryptic soy broth 
(30 g liter−1) and agar (15 g liter−1); Carl Roth] for 72 hours. Bacteria 
were detached and collected in 1 ml of 140 mM NaCl, which yielded 
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an optical density of ~160 at 600 nm. A sample (100 l) of this suspen-
sion was subjected to fractionation, whereas another 100-l sample 
was used to prepare whole-cell lysates. Bacteria were collected by cen-
trifugation (5 min at 3000g), and the supernatant was sterile-filtered 
before the BambL concentration in the extracellular space was de-
termined. The bacterial outer membrane was lysed for 30 min at 
room temperature in 500 l of 100 mM tris-HCl (pH 8) containing 
20% (w/v) sucrose, 2.5 mM EDTA, and 20 g of lysozyme (Sigma- 
Aldrich). Spheroblasts were collected by centrifugation (20 min at 
10,000g); the supernatant served as the periplasmic fraction. The 
spheroblasts were sonicated (Bandelin Sonopuls mini20, probe 
MS 2.5) in 500 l of 100 mM tris-HCl (pH 8), and undisrupted cells 
were separated by centrifugation (5 min at 5000g). The supernatant 
was centrifuged at 20,000g for 45 min to collect the membrane frac-
tion; the resulting supernatant was used as the cytoplasmic fraction. 
For Western blotting analysis, equivalent volumes of each cellular 
fraction were used to directly compare the relative amounts of 
BambL. Recombinantly produced BambL was loaded as a positive 
control. Samples were boiled with SDS–polyacrylamide gel electro-
phoresis sample buffer and separated in an 18% polyacrylamide gel, 
followed by electrophoretic transfer to a nitrocellulose membrane. 
After transfer, proteins were stained reversibly with Ponceau S solu-
tion (Sigma-Aldrich) and photographed. BambL was detected with 
a polyclonal antibody raised against its C terminus (Eurogentec) 
and an anti-rabbit IgG–horseradish peroxidase conjugate using the 
Clarity ECL kit (Bio-Rad).
Software and statistical analysis
Adobe Illustrator CC 2017 (Adobe) and Prism7 (GraphPad) software 
were used for figure preparation and statistical analysis, respectively. 
The statistical significance of the observed differences was evaluated 
by an unpaired, two-tailed Student’s t test (if not indicated otherwise). 
*P < 0.05, **P < 0.01, ***P < 0.001, **** P < 0.0001; ns, not signif-
icant. In the in vivo experiments, the exact P values are indicated; 




Fig. S1. Lectin binding and gating of HC−/− B cells.
Fig. S2. Gating schemes and IgD surface expression of specific B cell populations.
Fig. S3. Characterization of CD19-, IgM-, and IgD-deficient B cells.
Fig. S4. B220 is not internalized upon BambL binding.
Fig. S5. Internalization of CD86 and intracellular increase in TNF- in BambL-treated primary  
B cells.
Fig. S6. Stimulation of cells with BambL in the presence of cell death inhibitors.
Fig. S7. BambL binds to soluble Igs.
Fig. S8. Analysis of lymphoid lineage cells after in vivo injection of BambL.
Fig. S9. Analysis of myeloid lineage cells after in vivo injection of BambL.
Fig. S10. Non–B cells in the spleen show an increase in caspase activity upon BambL injection.
Fig. S11. BambL injection leads to splenomegaly and B cell accumulation in IgTMF mice.
Fig. S12. Mice treated with anti–IL-7R antibody exhibit splenomegaly and B cell proliferation in 
the spleen.
Fig. S13. B. ambifaria biofilms do not secrete BambL but retain it in the cytosol.
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antigens to hijack B cell signaling and stimulate rapid immune responses, which may pose a risk to immunocompromised
increased numbers of B cells and myeloid cells in the spleen. These data suggest that bacterial lectins may act like 
receptor and the kinase Syk. In vivo, these lectins induced a strong but transient immune response characterized by
that fucose-binding bacterial lectins bound to and activated mouse B cells in vitro, which depended on the B cell antigen 
 showedet al.enabling adhesion to host tissues and biofilm formation, which can lead to opportunistic infections. Wilhelm 
 species of proteobacteria secrete carbohydrate-binding proteins called lectins,Pseudomonas and Burkholderia
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